Protein levels of CC chemokine ligand (CCL)15, CCL16 and macrophage stimulating protein in patients with sarcoidosis
Language English Country Great Britain, England Media print
Document type Comparative Study, Journal Article, Research Support, Non-U.S. Gov't
PubMed
19220835
PubMed Central
PMC2669522
DOI
10.1111/j.1365-2249.2008.03832.x
PII: CEI3832
Knihovny.cz E-resources
- MeSH
- Analysis of Variance MeSH
- Biomarkers analysis MeSH
- Bronchoalveolar Lavage Fluid chemistry MeSH
- Chemokines, CC analysis MeSH
- Adult MeSH
- Enzyme-Linked Immunosorbent Assay MeSH
- Hepatocyte Growth Factor analysis MeSH
- Immunohistochemistry MeSH
- Macrophage Migration-Inhibitory Factors analysis MeSH
- Intramolecular Oxidoreductases analysis MeSH
- Middle Aged MeSH
- Humans MeSH
- Macrophage Inflammatory Proteins analysis MeSH
- Matrix Metalloproteinases analysis MeSH
- Young Adult MeSH
- Sarcoidosis, Pulmonary immunology MeSH
- Disease Progression MeSH
- Proto-Oncogene Proteins analysis MeSH
- Case-Control Studies MeSH
- Up-Regulation * MeSH
- Inflammation MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Young Adult MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Comparative Study MeSH
- Names of Substances
- Biomarkers MeSH
- CCL15 protein, human MeSH Browser
- CCL16 protein, human MeSH Browser
- Chemokines, CC MeSH
- Hepatocyte Growth Factor MeSH
- Macrophage Migration-Inhibitory Factors MeSH
- Intramolecular Oxidoreductases MeSH
- macrophage stimulating protein MeSH Browser
- Macrophage Inflammatory Proteins MeSH
- Matrix Metalloproteinases MeSH
- MIF protein, human MeSH Browser
- Proto-Oncogene Proteins MeSH
The objective of this study was to assess protein levels for candidate cytokines, chemokines, growth factors, matrix metalloproteinases and their inhibitors in bronchoalveolar lavage fluid (BALF) in patients with polar forms of pulmonary sarcoidosis, i.e. Löfgren's syndrome (LS) and more advanced chest X-ray (CXR) stage III disease. Twenty-four inflammatory molecules were analysed in unconcentrated BALF samples from 10 sarcoidosis patients with CXR stage III and 10 patients with LS by semiquantitative protein array. Four novel molecules [CC chemokine ligand (CCL)15, CCL16, macrophage migration inhibitory factor (MIF) and macrophage stimulating protein (MSP)], detected for the first time in association with sarcoidosis, were then quantified by enzyme-linked immunosorbent assay in a second cohort of 68 sarcoidosis patients and 17 control subjects. The protein levels of CCL15, CCL16, CCL24, CXCL8, CXCL9, CXCL10, interleukin-16, MIF, MSP and matrix metallopeptidase 1 were increased in CXR stage III patients when compared with patients with LS. CCL15 and MSP up-regulation in CXR stage III patients in comparison with LS patients and controls was confirmed by enzyme-linked immunosorbent assay. Moreover, MSP was associated with treatment requirement (P = 0.001) and CCL15 was elevated in patients with disease progression at 2-year follow-up (P = 0.016). CCL16 levels were increased in sarcoidosis versus controls (P < 0.05), but no difference was observed between patient subgroups. MIF up-regulation was not confirmed in a larger patient group. In conclusion, chemokines CCL15, CCL16 and MSP were found elevated for the first time in BALF from sarcoidosis patients; our results showed that CCL15 and MSP may affect disease course.
See more in PubMed
Baughman RP, Lower EE, du Bois RM. Sarcoidosis. Lancet. 2003;361:1111–18. PubMed
Kolek V. Sarcoidosis: known and unknown [in Czech] Prague: Grada Publishing; 1998.
American Thoracic Society, European Respiratory Society, World Association of Sarcoidosis and Other Granulomatous Disorders. Joint statement on sarcoidosis. Am J Respir Crit Care Med. 1999;160:736–55. PubMed
Zissel G, Prasse A, Müller-Quernheim J. Sarcoidosis – immunopathogenetic concepts. Semin Respir Crit Care Med. 2007;28:3–14. PubMed
Agostini C, Trentin L, Facco M, et al. Role of IL-15, IL-2, and their receptors in the development of T cell alveolitis in pulmonary sarcoidosis. J Immunol. 1996;157:910–18. PubMed
Gibejova A, Mrazek F, Subrtova D, et al. Expression of macrophage inflammatory protein-3 beta/CCL19 in pulmonary sarcoidosis. Am J Respir Crit Care Med. 2003;167:1695–703. PubMed
Petrek M, Kolek V, Szotkowská J, et al. CC and C chemokine expression in pulmonary sarcoidosis. Eur Respir J. 2002;20:1206–12. PubMed
Kriegova E, Melle C, Kolek V, et al. Protein profiles of bronchoalveolar lavage fluid from patients with pulmonary sarcoidosis. Am J Respir Crit Care Med. 2006;173:1145–54. PubMed
Pease JE, Williams TJ. The attraction of chemokines as a target for specific anti-inflammatory therapy. Br J Pharmacol. 2006;147(Suppl.)(1):S212–21. PubMed PMC
Gurrieri C, Bortoli M, Brunetta E, et al. Cytokines, chemokines and other biomolecular markers in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2005;22(Suppl.)(1):S9–14. PubMed
McDonnell S, Morgan M, Lynch C. Role of matrix metalloproteinases in normal and disease processes. Biochem Soc Trans. 1999;27:734–40. PubMed
Calandra T, Bucala R. Macrophage migration inhibitory factor (MIF): a glucocorticoid counter-regulator within the immune system. Crit Rev Immunol. 1997;17:77–88. PubMed
Wang MH, Zhou YQ, Chen YQ. Macrophage-stimulating protein and RON receptor tyrosine kinase: potential regulators of macrophage inflammatory activities. Scand J Immunol. 2002;56:545–53. PubMed
Chapman JT, Mehta AC. Bronchoscopy in sarcoidosis: diagnostic and therapeutic interventions. Curr Opin Pulm Med. 2003;9:402–7. PubMed
Sugiyama K, Mukae H, Ishii H, et al. Elevated levels of interferon gamma-inducible protein-10 and epithelial neutrophil-activating peptide-78 in patients with pulmonary sarcoidosis. Respirology. 2006;11:708–14. PubMed
Center DM, Berman JS, Kornfeld H, et al. The lymphocyte chemoattractant factor. J Lab Clin Med. 1995;125:167–72. PubMed
Ziegenhagen MW, Schrum S, Zissel G, et al. Increased expression of proinflammatory chemokines in bronchoalveolar lavage cells of patients with progressing idiopathic pulmonary fibrosis and sarcoidosis. J Invest Med. 1998;46:223–31. PubMed
Henry MT, McMahon K, Mackarel AJ, et al. Matrix metalloproteinases and tissue inhibitor of metalloproteinase-1 in sarcoidosis and IPF. Eur Respir J. 2002;20:1220–7. PubMed
O'Connor C, Odlum C, Van Breda A, et al. Collagenase and fibronectin in bronchoalveolar lavage fluid in patients with sarcoidosis. Thorax. 1988;43:393–400. PubMed PMC
Noor A, Knox KS. Immunopathogenesis of sarcoidosis. Clin Dermatol. 2007;25:250–8. PubMed
Ziegenhagen MW, Müller-Quernheim J. The cytokine network in sarcoidosis and its clinical relevance. J Intern Med. 2003;253:18–30. PubMed
Suga M, Iyonaga K, Ichiyasu H, et al. Clinical significance of MCP-1 levels in BALF and serum in patients with interstitial lung diseases. Eur Respir J. 1999;14:376–82. PubMed
Navratilova Z, Mrazek F, Kriegova E, et al. The MCP-1-2518 (A to G) single nucleotide polymorphism in Czech patients with pulmonary sarcoidosis: association with Löfgren's syndrome. Sarcoidosis Vasc Diffuse Lung Dis. 2007;24:33–8. PubMed
Keane MP, Standiford TJ, Strieter RM. Chemokines are important cytokines in the pathogenesis of interstitial lung disease. Eur Respir J. 1997;10:1199–202. PubMed
Skeel A, Leonard EJ. Action and target cell specificity of human macrophage-stimulating protein (MSP) J Immunol. 1994;152:4618–23. PubMed
Sakamoto O, Iwama A, Amitani R, et al. Role of macrophage-stimulating protein and its receptor, RON tyrosine kinase, in ciliary motility. J Clin Invest. 1997;99:701–9. PubMed PMC
Brunelleschi S, Penengo L, Lavagno L, et al. Macrophage stimulating protein (MSP) evokes superoxide anion production by human macrophages of different origin. Br J Pharmacol. 2001;134:1285–95. PubMed PMC
Gunella G, Bardelli C, Amoruso A, et al. Macrophage-stimulating protein differently affects human alveolar macrophages from smoker and non-smoker patients: evaluation of respiratory burst, cytokine release and NF-kappaB pathway. Br J Pharmacol. 2006;148:478–89. PubMed PMC
Schürmann M, Reichel P, Müller-Myhsok B, et al. Results from a genome-wide search for predisposing genes in sarcoidosis. Am J Respir Crit Care Med. 2001;164:840–6. PubMed
Pardigol A, Forssmann U, Zucht HD, et al. HCC-2, a human chemokine: gene structure, expression pattern, and biological activity. Proc Natl Acad Sci USA. 1998;95:6308–13. PubMed PMC
Youn BS, Zhang S, Broxmeyer HE, et al. Isolation and characterization of LMC, a novel lymphocyte and monocyte chemoattractant human CC chemokine, with myelosuppressive activity. Biochem Biophys Res Commun. 1998;247:217–22. PubMed
Youn BS, Zhang SM, Broxmeyer HE, et al. Characterization of CKbeta8 and CKbeta8-1: two alternatively spliced forms of human beta-chemokine, chemoattractants for neutrophils, monocytes, and lymphocytes, and potent agonists at CC chemokine receptor 1. Blood. 1998;91:3118–26. PubMed
Haringman JJ, Smeets TJ, Reinders-Blankert P, et al. Chemokine and chemokine receptor expression in paired peripheral blood mononuclear cells and synovial tissue of patients with rheumatoid arthritis, osteoarthritis, and reactive arthritis. Ann Rheum Dis. 2006;65:294–300. PubMed PMC
Ziegenhagen MW, Rothe ME, Schlaak M, et al. Bronchoalveolar and serological parameters reflecting the severity of sarcoidosis. Eur Respir J. 2003;21:407–13. PubMed
Tutor-Ureta P, Citores MJ, Castejón R, et al. Prognostic value of neutrophils and NK cells in bronchoalveolar lavage of sarcoidosis. Cytometry B Clin Cytom. 2006;70:416–22. PubMed
Cappello P, Caorsi C, Bosticardo M, et al. CCL16/LEC powerfully triggers effector and antigen-presenting functions of macrophages and enhances T cell cytotoxicity. J Leukoc Biol. 2004;75:135–42. PubMed
Genetic control of CCL24, POR, and IL23R contributes to the pathogenesis of sarcoidosis
The Serum Expression of Selected miRNAs in Pulmonary Sarcoidosis with/without Löfgren's Syndrome